BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) CEO Vimal Mehta sold 126,014 shares of the firm’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $1.63, for a total transaction of $205,402.82. Following the transaction, the chief executive officer now directly owns 7,811,515 shares of the […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) CEO Vimal Mehta sold 126,014 shares of BioXcel Therapeutics stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $1.63, for a total transaction of $205,402.82. Following the transaction, the chief executive officer now directly owns 7,811,515 shares […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 1,630,000 shares, a growth of 8.7% from the April 30th total of 1,500,000 shares. Based on an average daily trading volume, of 584,400 shares, the days-to-cover […]
Clinicians at Georgetown University s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a Phase II clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda). Immunotherapy drugs alone have not shown to be responsive to pancreatic cancer.
28.05.2024 - NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) - BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced . Seite 1